{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:18:38Z","timestamp":1790313518406,"version":"4.1.0"},"reference-count":25,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030825","name":"Ascendis Pharma A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030825","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Investigator-Initiated Research Grant"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Replacement therapy with recombinant human PTH (rhPTH1-84) represents a causal treatment for patients with chronic hypoparathyroidism (HypoPT). Recently, palopegteriparatide (TransCon PTH), a novel long-acting drug with slow release of PTH1-34, was approved by the European Medicines Agency and Food and Drug Administration for treatment of HypoPT. To date, no data exist on the treatment switch from rhPTH1-84 to TransCon PTH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively analyzed clinical data from 40 patients with chronic HypoPT during the switch from rhPTH1-84 to TransCon PTH. Independent of the last prior rhPTH1-84 dose, all patients were started on 18\u2005\u00b5g of TransCon PTH as recommended by the manufacturer. TransCon PTH dose adjustments, changes in additional medication, and adverse events were documented during the treatment switch.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Within the first month after the treatment switch, 80% (n = 32) of patients needed individual adjustment of their TransCon PTH dose to achieve normocalcemia. Dose reduction (to 9-15\u2005\u00b5g) was necessary in 38% (n = 15) and an increase (to 21-27\u2005\u00b5g) in 43% (n = 17) of patients. Adjustments occurred predominantly (in 62% cases) according to serum calcium levels, partly dependent on symptoms. The prior applied rhPTH1-84 dose correlated significantly with the adjusted TransCon PTH dose (r = 0.4; P = .01). The treatment change was associated with moderate or mild adverse events in 24\/40 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We hereby report the first clinical data on switching treatment from rhPTH1-84 to 18\u2005\u00b5g TransCon PTH independent of the prior rhPTH1-84 dose. Our data support discrete adaptation of the starting dose depending on the prior rhPTH1-84 dosage.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf113","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:08:23Z","timestamp":1751288903000},"source":"Crossref","is-referenced-by-count":5,"title":["Switch From rhPTH1-84 to TransCon PTH With Individual Dose Adjustment in Adult Hypoparathyroidism\u20144-Week Results"],"prefix":"10.1210","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8366-8625","authenticated-orcid":false,"given":"Heide","family":"Siggelkow","sequence":"first","affiliation":[{"name":"Department of Trauma, Orthopedics and Reconstructive Surgery, University Medical Center G\u00f6ttingen , G\u00f6ttingen 37075 ,","place":["Germany"]},{"name":"MVZ endokrinologikum G\u00f6ttingen, Center for Endocrinology, Osteology, Rheumatology, Nulear Medicine and Human Genetics , G\u00f6ttingen 37075 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A","family":"Peschke","sequence":"additional","affiliation":[{"name":"Department of Trauma, Orthopedics and Reconstructive Surgery, University Medical Center G\u00f6ttingen , G\u00f6ttingen 37075 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Bone Diseases, Department of Medicine III, University Center for Healthy Aging, Technische Universit\u00e4t Dresden , Dresden 01307 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C","family":"Hofbauer","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Bone Diseases, Department of Medicine III, University Center for Healthy Aging, Technische Universit\u00e4t Dresden , Dresden 01307 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M","family":"Berr","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, I. Medical Clinic, University Hospital, University of Augsburg , Augsburg 86156 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hahner","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Endocrinology and Diabetes, University of W\u00fcrzburg , W\u00fcrzburg 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-4392","authenticated-orcid":false,"given":"Christian","family":"Lottspeich","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital , LMU Munich 80336 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schmidmaier","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital , LMU Munich 80336 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Blaschke","sequence":"additional","affiliation":[{"name":"MVZ endokrinologikum G\u00f6ttingen, Center for Endocrinology, Osteology, Rheumatology, Nulear Medicine and Human Genetics , G\u00f6ttingen 37075 ,","place":["Germany"]},{"name":"Clinic of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center G\u00f6ttingen , G\u00f6ttingen 37075 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2025072403115561300_bvaf113-B1","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2025072403115561300_bvaf113-B2","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025072403115561300_bvaf113-B3","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025072403115561300_bvaf113-B4","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/jbmr.4716","article-title":"Management of hypoparathyroidism","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2025072403115561300_bvaf113-B5","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/jbmr.4673","article-title":"Complications, symptoms, presurgical predictors in patients with chronic hypoparathyroidism: a systematic review","volume":"37","author":"Yao","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025072403115561300_bvaf113-B6","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025072403115561300_bvaf113-B7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jbmr.3368","article-title":"Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study","volume":"33","author":"Underbjerg","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025072403115561300_bvaf113-B8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/jbmr\/zjaf061","article-title":"Increased risk of vertebral fractures and reduced risk of femur fractures in patients with chronic hypoparathyroidism: a nationwide cohort study in Sweden","volume":"40","author":"Bjornsdottir","year":"2025","journal-title":"J Bone Miner Res"},{"key":"2025072403115561300_bvaf113-B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf257","article-title":"Increased risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden","author":"Bjornsdottir","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025072403115561300_bvaf113-B10","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025072403115561300_bvaf113-B11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"issue":"5","key":"2025072403115561300_bvaf113-B12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"2025072403115561300_bvaf113-B13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025072403115561300_bvaf113-B14","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8\u2013year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025072403115561300_bvaf113-B15","doi-asserted-by":"crossref","first-page":"bvad043","DOI":"10.1210\/jendso\/bvad043","article-title":"Long-term safety and efficacy of recombinant human parathyroid hormone (1-84) in adults with chronic hypoparathyroidism","volume":"7","author":"Watts","year":"2023","journal-title":"J Endocr Soc"},{"issue":"11","key":"2025072403115561300_bvaf113-B16","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025072403115561300_bvaf113-B17","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025072403115561300_bvaf113-B18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025072403115561300_bvaf113-B19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025072403115561300_bvaf113-B20","first-page":"319","article-title":"Self-report of psychological symptoms in hypoparathyroidism patients on conventional therapy","volume":"62","author":"Arneiro","year":"2018","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"2025072403115561300_bvaf113-B21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40271-019-00388-5","article-title":"Assessing the patient experience of hypoparathyroidism symptoms: development of the hypoparathyroidism patient experience scale-symptom (HPES-symptom)","volume":"13","author":"Brod","year":"2020","journal-title":"Patient"},{"issue":"2","key":"2025072403115561300_bvaf113-B22","doi-asserted-by":"crossref","first-page":"e10586","DOI":"10.1002\/jbm4.10586","article-title":"The influence of conventional treatment on symptoms and complaints in patients with chronic postsurgical hypoparathyroidism","volume":"6","author":"Stamm","year":"2022","journal-title":"JBMR Plus"},{"issue":"2","key":"2025072403115561300_bvaf113-B23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eprac.2024.10.017","article-title":"Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis","volume":"31","author":"Tabatabai","year":"2025","journal-title":"Endocr Pract"},{"key":"2025072403115561300_bvaf113-B24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/978-1-4684-4259-5_64","article-title":"Vascular effects of parathyroid hormone (PTH)","volume":"151","author":"Rambausek","year":"1982","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2025072403115561300_bvaf113-B25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0303-7207(89)90231-1","article-title":"Parathyroid hormone acute vascular effect is mediated by decreased Ca2+ uptake and enhanced cAMP level","volume":"67","author":"Schleiffer","year":"1989","journal-title":"Mol Cell Endocrinol"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf113\/63629245\/bvaf113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/9\/bvaf113\/63629245\/bvaf113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/9\/bvaf113\/63629245\/bvaf113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:12:06Z","timestamp":1753341126000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf113\/8178763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf113","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,30]]},"article-number":"bvaf113"}}